Fonar Corp, founded in 1978 and headquartered in Melville, New York, is a pioneer in US medical diagnostic technology. After founder Dr. Raymond Damadian invented the world's first commercial MRI scanner, the company went on to carve out a unique niche with its "Stand-Up Multi-Position MRI," which allows imaging without requiring patients to lie down. Today, through its subsidiary HMCA, the company provides management services for dozens of diagnostic imaging centers across New York and Florida, operating as a medical solutions company with both technological capabilities and service expertise.

💰 How does it make money?

Fonar generates the overwhelming majority of its revenue from diagnostic center management services rather than traditional equipment sales. This translates into a stable revenue structure, with recurring monthly management fees, and its recent annual revenue stands at approximately $105.3M.

Market cap is $119.9M, roughly About 0% of Samsung Electronics' market cap. The company employs 535 people people.

Fonar's market cap stands at approximately $119.9M, which is about About 0% the size of Samsung Electronics' market cap. Approximately 535 people employees are dedicated to producing innovative medical devices and managing high-quality diagnostic services.

📈 Fonar Outlook and Stock Price Trends

Recently, Fonar has been undergoing a management-led delisting and take-private transaction process. This move is designed to secure long-term strategic flexibility for the company, and the share price is expected to converge near the merger consideration of $19 per share going forward. Backed by solid growth in its services segment, the company is steadily maintaining +2.3% and 9.1% metrics, and these financial results are expected to underpin corporate value until the take-private process is completed.

⚔️ Key Competitive Strengths and Risks

A medical technology company where proprietary MRI core technology and stable cash flow from center management go hand in hand.

🔄 Competitors and Related Stocks (Beneficiaries)

Key competitors include global medical device giants such as GE HealthCare (GEHC) and Siemens Healthineers, as well as smaller medical equipment players such as Apyx Medical (APYX) and Utah Medical (UTMD). Each competes for diagnostic market share on the basis of its own specialized technological capabilities.

✅ Investor Checkpoints

Three key checkpoints that must be verified before investing in Fonar.

Once the delisting process is completed, trading in the stock market will no longer be possible, so investors should carefully weigh the merger terms against their own investment objectives.

Fonar is a well-established company that has grown alongside the history of MRI technology. It is a stock that warrants a cautious approach, with attention to the nature and final value of the ongoing go-private transaction.

Check out Fonar's real-time quotes, technical indicators, and peer comparisons all in one place on US Stock Today's real-time dashboard.